LCTX — Lineage Cell Therapeutics Balance Sheet
0.000.00%
- $112.05m
- $63.00m
- $9.50m
- 31
- 24
- 15
- 11
Annual balance sheet for Lineage Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 41.6 | 58.4 | 57.9 | 35.5 | 47.8 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.004 | 50.8 | 0.297 | 0.745 | 0.638 |
Prepaid Expenses | |||||
Total Current Assets | 44 | 112 | 60 | 38.4 | 51 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.63 | 4.87 | 5.67 | 4.77 | 4.39 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 108 | 175 | 124 | 101 | 113 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.77 | 47.1 | 19 | 18 | 14 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.8 | 82.3 | 50.3 | 37.6 | 34.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 96.2 | 92.2 | 73.3 | 63.4 | 78.4 |
Total Liabilities & Shareholders' Equity | 108 | 175 | 124 | 101 | 113 |
Total Common Shares Outstanding |